Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | City of Hope | 24 |
| 2 | Mallinckrodt PLC | 18 |
| 3 | Merck and Co Inc | 17 |
| 4 | University of California | 16 |
| 5 | Verastem Inc | 10 |
| 6 | Bayer AG | 8 |
| 7 | Instil Bio Inc | 6 |
| 8 | Roche Holding AG | 6 |
| 9 | Syndax Pharmaceuticals Inc | 6 |
| 10 | Weizmann Institute of Science | 6 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 305 |
| 2 | A61P | Therapeutic activity (drug indications) | 270 |
| 3 | C07K | Peptides | 101 |
| 4 | C07D | Heterocyclic compounds | 85 |
| 5 | C12N | Microorganisms, enzymes | 48 |
| 6 | G01N | Investigating / analysing materials | 38 |
| 7 | C12Q | Measuring/testing involving enzymes | 30 |
| 8 | A61N | 17 | |
| 9 | Y02A | Climate change adaptation | 16 |
| 10 | A61B | 15 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | 2022 | Merck and Co Inc | 23 |
| SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT | 2022 | Merck and Co Inc | 20 |
| COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | 2023 | The Francis Crick Institute Ltd | 9 |
| TREATMENTS FOR CANCERS HAVING KRAS MUTATIONS | 2022 | City of Hope | 11 |
| Conjugate, target tumor active oxygen response medicament-carried nano micelle and preparation method and application | 2018 | 19 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 11 |
| 2017 | 11 |
| 2018 | 12 |
| 2019 | 11 |
| 2020 | 6 |
| 2021 | 6 |
| 2022 | 4 |
| 2023 | 5 |
| 2024 | 4 |
| 2025 | 3 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | François Guillemin | Délégation Centre-Est | 35 |
| 2 | Colin Hopper | University College London | 24 |
| 3 | Georges Wagnières | École Polytechnique Fédérale de Lausanne | 22 |
| 4 | Alfred Fahr | Friedrich Schiller University Jena | 22 |
| 5 | Lina Bezdetnaya | CRAN | 14 |
| 6 | I. Bing Tan | The Netherlands Cancer Institute | 13 |
| 7 | Hugo Oppelaar | The Netherlands Cancer Institute | 12 |
| 8 | Ilya Yakavets | Université de Lorraine | 9 |
| 9 | Henricus J. C. M. Sterenborg | Erasmus University Rotterdam | 9 |
| 10 | Daniel Braichotte | École Polytechnique Fédérale de Lausanne | 8 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| PHOTODYNAMIC THERAPY | 1993 | 390 | Nanoplatforms for cancer theranostics |
| Combining Magnetic Hyperthermia and Photodynamic Therapy for Tumor Ablation with Photoresponsive Magnetic Liposomes | 2015 | 332 | Nanoparticle-Based Drug Delivery |
| Temoporfin (Foscan ® , 5,10,15,20‐Tetra( m ‐hydroxyphenyl)chlorin)—A Second‐generation Photosensitizer †,‡ | 2011 | 300 | Photodynamic Therapy Research Studies |
| Assessment of Apoptosis by Immunohistochemistry to Active Caspase-3, Active Caspase-7, or Cleaved PARP in Monolayer Cells and Spheroid and Subcutaneous Xenografts of Human Carcinoma | 2008 | 251 | Cell death mechanisms and regulation |
| Temoporfin-loaded invasomes: Development, characterization and in vitro skin penetration studies | 2008 | 228 | Essential Oils and Antimicrobial Activity |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular composition of Temoporfin?
Which organizations hold the most patents related to Temoporfin?
What is the recent patent activity trend for Temoporfin?
Who are the most prolific researchers publishing on Temoporfin?
What are the main patent classification areas for Temoporfin-related inventions?